Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer

NCT ID: NCT01400620

Last Updated: 2018-03-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2017-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether an oral rinse composed of botanical extracts is effective in the prevention of severe inflammation of the lining of the oral cavity caused by chemotherapy and radiation therapy for head and neck cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oral Mucositis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active oral rinse

Oral rinse containing botanical extracts

Group Type EXPERIMENTAL

IZN-6N4

Intervention Type DRUG

Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks

Placebo rinse

Group Type PLACEBO_COMPARATOR

IZN-6N4

Intervention Type DRUG

Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IZN-6N4

Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of head and neck cancer
* planned treatment course to include Cisplatin and radiation therapy, cumulative prescription dose between 50-70 Gy
* able to eat at least soft solids
* normal cardiac function
* able to perform oral rinse

Exclusion Criteria

* Induction chemotherapy regimen
* life threatening allergic reaction to food and/or drugs
* history of any other primary malignancy diagnosed within the past 5 years
* prior radiation to the sites to be treated
* active infections of the oral cavity
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Izun Pharma Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UF Health Cancer Center

Gainesville, Florida, United States

Site Status

University of Miami-Sylvester CCC Clinical Research Services

Miami, Florida, United States

Site Status

Mount Sinai Beth Israel - Phillips Ambulatory Care Center

New York, New York, United States

Site Status

NYU Clinical Cancer Center

New York, New York, United States

Site Status

Soroka Medical Center

Beersheba, , Israel

Site Status

Rambam Medical Center

Haifa, , Israel

Site Status

Rabin Medical Center - Beilinson Campus

Petah Tikva, , Israel

Site Status

Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Assuta Medical Center

Tel Aviv, , Israel

Site Status

Sheba Medical Center

Tel Litwinsky, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Israel

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IOM-HNC-201-IL

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.